VCM
BMRN icon

Voleon Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Voleon Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81M Sell
32,074
-20,680
-39% -$1.21M 0.04% 348
2025
Q4 		$3.14M Sell
52,754
-13,027
-20% -$709K 0.07% 275
2025
Q3 		$3.56M Buy
65,781
+61,662
+1,497% +$3.53M 0.09% 232
2025
Q2 		$226K Buy
+4,119
New +$243K 0.01% 448

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voleon Capital Management's BMRN Position: Q1 2026 in Review

Voleon Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 39% in Q1 2026, selling an estimated $1.21M and leaving 32,074 shares worth $1.81M. The position accounts for 0.04% of the portfolio, ranked #348.

Voleon Capital Management first reported a position in BMRN in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.56M in Q3 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Voleon Capital Management held 32,074 shares of BioMarin Pharmaceuticals worth $1.81M as of Q1 2026.
  • Voleon Capital Management sold 20,680 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.21M.
  • BioMarin Pharmaceuticals made up 0.04% of Voleon Capital Management's portfolio in Q1 2026, its #348 holding.
  • Voleon Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Voleon Capital Management's BioMarin Pharmaceuticals position peaked at $3.56M in Q3 2025.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.